Ultra Nasdaq Biotechnology 2X ETF BIB

— +— (—)

Valuation

Market cap
—
Revenue TTM
—
Net income TTM
—
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
—
Avg volume
—
Day's range
—
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Latest news

Stocktwits

macrossluvsrobotech Oct 2, 6:17 PM
$LXRX The Amylin Trap vs. Oral ACSL5 Solution 🧬💊 $LLY BE TRYIN ... but $NVO has a secret weapon 😎 = CNBC reports Lilly & Novo are racing into amylin combinations, pushing 23% weight loss—but hitting a wall with up to 27% of patients dropping out from severe nausea/vomiting! Why Lexicon's ACSL5 (partnered with Novo) solves this: 1. Synthetic Overload vs Natural Release: Stacking injectable peptides (EloraTZP/CagriSema) floods brainstem receptors with artificial hormones, requiring multi-billion-dollar cold-chain CapEx. ACSL5 is an oral small molecule acting locally in the gut to trigger the body's natural "ILEAL BRAKE," releasing endogenous GLP-1 & PYY. 2. Slide 10 Proof: Novo confirmed "Improved tolerability vs GLP-1s," zero titration steps, and -33% weight loss combined with sema 3. Bolt-On M&A: Novo needs oral non-incretins to counter Lilly. LXRX’s ~$770M EV is a pure value play. CNBC: https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html $NVO $LLY $BIB $VTRS
0 replies
macrossluvsrobotech Oct 2, 6:05 PM
$LXRX Q4 Intelligence: Sota T1D, Cantor $8 PT & M&A 🏛️🧬 Fresh updates on Lexicon ($LXRX) as Q4 2026 opens: 1. Cantor $8 Price Target: Cantor Fitzgerald initiated coverage with an Overweight rating and an $8.00 target (>340% upside), joining Wall Street Buy upgrades into year-end. 2. Sota T1D Resubmission: Zynquista NDA refiling on track for Q4 2026, backed by STENO-1 real-world safety data. 3. Political Tailwinds: With HHS Secretary RFK Jr. pushing the MAHA chronic disease agenda into the midterms, approving the 1st oral pill to reduce daily insulin injections delivers a major win for chronic illness reform. 4. M&A Heat: Lilly’s $6.5B Houston plant pressures Novo (CMD Slide 13 bolt-on plan) to acquire LXRX (~$770M EV) ahead of Q1 '27 HCM Phase 3 & ACSL5 ). Cantor Note: https://www.marketbeat.com/instant-alerts/analyst-lexicon-pharmaceuticals-nasdaq-lxrx-coverage-initiated-by-analysts-at-cantor-fitzgerald-2026-09-28/ $NVO $LLY $VTRS $BIB
0 replies
macrossluvsrobotech Sep 23, 5:05 PM
$LXRX + $NVO Catalyst Wire: STENO-1 Complete, M&A Arbitrage & Global Deals ⚖️🧬 Confirmed intelligence from September filings & conferences: 1. STENO-1 Complete: Patient exposure requirements are done, clearing the path for the Q4 2026 Zynquista T1D FDA NDA resubmission. 2. Novo M&A Arbitrage: Novo CMD Slide 13 confirms active pursuit of "bolt-on acquisitions" (citing Forma, Dicerna)[span_4](start_span)[span_4](end_span). LXRX’s ~$770M EV sits below Novo's $1.0B contract for LX9851 alone. 3. Partner Momentum: Viatris secured heart failure approvals in UAE & Bahrain. LXRX is in talks to partner Pilavapadin Phase 3. 4. Executive Leverage: CMO Granowitz confirmed strong cash allows LXRX to maximize value before striking new deals. HCW Source: https://tinyurl.com/lxrx-hcw Novo CMD: https://tinyurl.com/novo-cmd26 $BIB $VTRS $LLY
0 replies
macrossluvsrobotech Sep 19, 5:38 PM
$LXRX + $NVO $LXRX + $VTRS Discovery Signal: AI Unlocking Genome5000 Dr. Suma Gopinathan (Lexicon SVP Discovery) liked Vinoth Sittaramane’s post on scaling healthcare AI and clinical workflow integration. Why it matters for $LXRX: 1. Mining Genome5000: Lexicon owns ~5,000 proprietary gene knockouts. An AI query layer over this 30-yr vault monetizes dormant oncology & metabolic targets with zero wet-lab cash burn. 2. Frictionless REMS: Sittaramane stressed clinical workflow integration. Automating ketone alerts in hospital EHRs solves the FDA T1D DKA hurdle without administrative red tape. 3. Estate Value: Gopinathan led discovery for Sota, LX9851, and AAK1. Tracking scalable AI architecture signals how LXRX will package unmonetized IP for pharma licensing deals. Under-the-radar AI biotech asset. Novo Nordic steel of $1BIL÷445mil shares of lexicon equals $2.47 a share just on that one deal not counting entire pipeline& $.30 of cash making a total 2.77 a share fair market. $BIB
0 replies
macrossluvsrobotech Sep 11, 4:31 PM
$LXRX Just in 1bil from Novo, puts our share value at: 2.47 ... our cash is .30 cent a share. Meaning, FAIR MARKET VALUE JUST ON NOVO AND CASH? 2.77 a share. NOT COUNTING THE SUBMITTAL=AND EVERYTHING ELSE= I SAID .80 CENTS IN PRIOR POSTS IN INCREMENTAL ROYALTIES... ON TOP OF THIS OBVIOUS VALUATION...I SHOULD HAVE BEEN CLEARER. 445 mil shares divided by 1 bil = 2.47 a share. PLUS .30 cents from our cash. ALONE put's us at 2.77 a share. NOT COUNTING THE MINIMUM .80 CENT ROYALTY MINIMUM VALUE PER SHARE IN THE FUTURE FROM REVENUE SHARE SALES. WHICH EASILY PUTS US AT 3.05 SHARE. $NVO $VTRS $BIB $SPY = ( AI SOFTWARE LAYER FACTOR FOR GENOME 5,000 VAULT, WITH OTHER INDICATIONS AND ONCOLOGY AS AN EXAMPLE, AND MENTIONED )
1 replies
macrossluvsrobotech Sep 11, 4:04 PM
$LXRX — count the VALUE/estate, not just the 'ticker'. Novo LX9851 (oral obesity / fat-metabolism pill): up to $1B headline. $75M already in. Rest = milestones (goal payments) + royalties (sales cut). Easy minimum, floor value per share ≈ $0.80/sh. Zynquista T1D (type 1 diabetes): ~1M US adults. No approved *oral* add-on to minimize need 4 daily painful insulin jab. FIRST OF ITS KIND- IN THE U.S. Q4 FDA file (Oct–Dec). Efficacy accepted!!!!!!!!. Gate was DKA (dangerous acid buildup). STENO-1 (Denmark safety study) was that gate. Minimum value in sales per share: ≈ $2.20/sh. SONATA + AAK1 appx minimum value per share ≈ $1.45/sh. SONATA = P3 (late trial) in HCM (thick stiff heart), Q1’27. Camzyos ( another similar brand, inferior ) already banks ~$1B+/yr; no nHCM . AAK1 = pilavapadin, non-opioid for DPNP (diabetic nerve pain). P3 = partner’s check, but could be 1.80-3.80 minimum value per share in royalties. Add: ~$6.80–8.80+ vs ~$2. Not a promise. A ledger. $NVO $VTRS $BIB $SPY
0 replies
SniperPro Sep 10, 11:30 AM
$LXRX $NVO $VTRS $BIB $SPY 🤑 Amazing presentation!!! 🤑 🚀💪💰 IF YOU’RE LOOKING TO PARTNER, THIS IS ONE TO WATCH. 🤝🔥
0 replies
macrossluvsrobotech Sep 9, 11:03 PM
$LXRX Citi Webcast Takeaways — Disciplined Execution Over Hype 🧬📊 1. T1D NDA (Zynquista): Targeted for Q4 submission. Exton confirmed the Steno-1 exposure hurdle was hit in late August: "Data is done... preparing it and getting ready to submit." DKA rate came in lower than inTandem and similar to standard of care, meeting FDA's stated risk-benefit criteria. 2. HCM (North Star) Q1 '27: SONATA-HCM over-enrolled past 500 patients across 130+ sites. Broad EF range plus a unique background CMI cohort. Management framed a +3-pt placebo-adjusted KCCQ delta as a commercial home run. 3. Capital Discipline on Pain: Pilavapadin (LX9211) won’t drain cash in a self-funded Phase 3. Presenting new cardiometabolic preclinical data later this year to bundle into an expanded partnership package. 4. Genome 5000 + AI: Evaluating an AI query layer over 30 years of proprietary knockout data (origin of Sota, LX9851, LX9211) to explore untouched oncology/immuno. Pure optionality. $NVO $VTRS $BIB $SPY
2 replies